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ABSTRACT
We reviewed liver histologic results from all allogeneic hematopoietic stem cell transplant recipients from our
institution with a confirmed diagnosis of liver graft-versus-host disease (L-GVHD), no concomitant causes of
liver dysfunction, and at least 1 diagnostic liver biopsy sample (n  33) to ascertain whether histologic features
predicted clinical outcome. The 1-year probability of nonrelapse mortality (NRM) from the onset of liver
dysfunction was 68.15%, with a median overall survival (OS) of 6.2 months for the entire group. Histologic
features traditionally linked to the diagnosis of L-GVHD (eg, bile duct damage, bile duct lymphocytic
infiltration, portal inflammation, and ductopenia) had no association with patient outcome. However, an
extended histologic analysis showed that a high level of lobular inflammation (LI) and a low level of hepatocyte
ballooning (HB) were independent favorable prognostic factors for NRM (RR, 5.14; P  .033; and relative risk
(RR), 0.18; P  .018, respectively) and OS (RR, 3.99; P  .032; and RR, 0.23; P  .037, respectively). The
presence and severity of LI and HB were not associated with patient- or transplant-related characteristics or
L-GVHD clinical factors such as timing of the biopsy from the onset of L-GVHD, acute versus chronic
presentation, or whether the patients had started immunosuppressive treatment with steroids at the time of the
biopsy. In multivariate analysis that included clinical prognostic factors, the combined histologic risk posed by
high LI and low HB retained independent favorable prognostic value for NRM (RR, 5.05; P  .015) and OS
(RR, 3.31; P  .038). This information, if replicated in other studies, could expand current indications for liver
biopsy in patients with L-GVHD, not only to exclude other causes of liver injury, but also to predict clinical
outcome, and should be considered in the selection of patients and the design of future trials with new
experimental therapies for this complication. Prospective validation of our findings is warranted.
© 2005 American Society for Blood and Marrow Transplantation
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rNTRODUCTION
Graft-versus-host disease (GVHD) is a major
ause of morbidity and mortality in patients who un-
ergo allogeneic hematopoietic stem cell transplanta-
ion (allo-HSCT) [1-3]. Patients with GVHD involv-
ng visceral organs, in particular the liver (L-GVHD),
re less likely to respond to treatment, and they have
n extremely poor outcome [4-7]. The assessment of
everity of L-GVHD relies on grading systems based
n clinical changes (ie, serum bilirubin level) and, as h
B&MTor other target organs, does not consider histologic
eatures, which are regarded as inadequate for this
urpose [8-10]. Thus, current understanding remains
hat liver biopsies should be performed in this setting
nly to rule out other causes of liver injury (eg, viral
nfection or drug toxicity) when isolated L-GVHD is
uspected and when the biopsy result may lead to a
adical therapeutic change [11,12].
In this study, we sought to ascertain whether liver
istology in this setting would be of value not only to
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8ule out causes of liver injury after allo-HSCT other
han L-GVHD, but also to predict the clinical out-
ome of patients with L-GVHD. We had analyzed the
utcome and clinical prognostic factors of all cases of
-GVHD diagnosed at the Royal Free Hospital from
978 to September 2003 [7]. For the purpose of this
tudy, we reviewed the liver histology of those cases
ith conﬁrmed diagnosis of L-GVHD, no other con-
omitant causes of liver dysfunction, and at least 1
iagnostic liver biopsy. Our ﬁndings show that the
istologic features in the ﬁrst diagnostic liver biopsy
ave an independent prognostic value for predicting
he clinical outcome of patients with L-GVHD.
ATIENTS AND METHODS
One hundred nine of 767 recipients of an allo-
SCT at the Royal Free Hospital from 1978 to Sep-
ember 2003 had disease diagnosed as L-GVHD [7].
orty-six (42%) of these patients had at least 1 diagnostic
iver biopsy and had extensive scrutiny of their medical
ecords and review of their histologic results. Patients
eceived conﬁrmed diagnoses of L-GVHD upon review
f they had progressive increases in serum liver enzyme
evels after transplantation and/or donor lymphocyte in-
usion (DLI) suggestive of L-GVHD and if no other
auses could be identiﬁed by history, physical examina-
ion, and standard screening tests [13]. Brieﬂy, patients
ad to have no history of new drug exposure and no
ecent change in the dose or schedule of their routine
edications. Routine bacterial and fungal cultures were
btained to rule out ongoing subtle infections. The pos-
ibility of viral hepatitis caused by hepatitis A, B, or C
irus; herpes simplex virus; and varicella zoster virus was
uled out by standard serologic tests. In the appropriate
osts, evidence of primary infection or reactivation of
ytomegalovirus was sought, and, since 1993, cytomeg-
lovirus polymerase chain reaction analysis was routinely
erformed at least weekly. Radiologic studies, including
bdominal ultrasonography or computed tomography,
ere conducted to rule out the presence of an obstruc-
ive or intraparenchymal lesion. Eight of 46 cases were
xcluded from the study on the basis of clinical criteria,
ncomplete information, or both.
Histologic sections were reviewed by 2 histo-
athologists independently, prospectively, and with-
ut access to the original histologic diagnoses, the
resence of GVHD in other tissues, or speciﬁc clinical
ata. Final assessments, scores, and histologic diag-
oses were reached by discussion. Histologic review
as performed in 2 stages. First, all biopsy samples
ere assessed for histologic features of L-GVHD and
o identify liver pathology other than L-GVHD. No
ttempt was made to analyze the outcome of
-GVHD, even with biopsy evidence of L-GVHD,f a concomitant liver complication other than d
06-GVHD was known to be present at any time. Thus, 5
atients were excluded from the ﬁnal analysis on the
asis of this initial histological analysis in addition to
hose excluded by the clinical criteria described previ-
usly. Only patients with at least 1 liver biopsy and
onﬁrmed diagnosis of L-GVHD after both clinical and
nitial histological analyses in which no other causes of
iver dysfunction were present underwent a second de-
ailed histologic review of their individual histologic fea-
ures (Histology Study Group). In addition to features
onsistent with a diagnosis of L-GVHD, which tradi-
ionally involve the epithelium of the biliary canal with
ymphocytic inﬁltrates mainly localized in portal tracts,
his second stage of the histology review extended to a
ider array of histologic features. The following were
ssessed and scored according to established semiquan-
itative scoring systems adapted for this study [14-16]:
poptosis, arteritis, bile duct damage, bile duct lympho-
ytic inﬁltration, canalicular cholestasis, ductopenia
present or absent), ductular reaction, endotheliitis, he-
atocyte ballooning (HB), lobular inﬂammation (LI),
eriductular ﬁbrosis (present or absent), periductular
ymphocyte aggregates (present or absent), portal in-
ammation, and siderosis. In 15 patients who underwent
ore than 1 liver biopsy (range, 2-5), outcome was
nalyzed with the results of the ﬁrst diagnostic biopsy.
Response to primary treatment was deﬁned by
eduction in the serum bilirubin level to 2 mg/dL
or patients with baseline values of 2 to 4 mg/dL, a
ecrease of 2 mg/dL for patients with baseline val-
es of 4 to 8 mg/dL, or 25% decrease for patients
ith baseline values of 8 mg/dL. Response was as-
essed at a nonﬁxed time point according to the values
t 4 weeks from the start of primary treatment, the
alues at the initiation of secondary treatment, or the
ast recorded values before death, whichever occurred
rst, as described previously [4]. Nonrelapse mortality
NRM) and overall survival (OS) curves were esti-
ated by using the Kaplan-Meier method and com-
ared by using the log-rank test. Multivariate analysis
as performed according to the Cox proportional
azards regression model. Contingency table analyses
ere performed with 2 or Fisher exact tests, as ap-
ropriate. All statistical calculations used SPSS 11.0
SPSS Inc., Chicago, IL); P values of .05 were con-
idered signiﬁcant. P values were unadjusted for mul-
iple signiﬁcance tests.
ESULTS
Thirty-three patients were included in the histol-
gy study group after the initial clinical and histologic
eview. Patient characteristics are summarized in
able 1; patients were compared with the reference
opulation of L-GVHD patients with a conﬁrmed
iagnosis of L-GVHD based on the same criteria of
c
c
d
1
o
1
L
a
d
d
p
(
a
p
p
n
a
n
i
e
p
t
(
b
T
A
M
U
D
S
D
C
G
O
E
L
T
A
D .
Histologic Features Predict the Outcome of Liver GVHD
Blinical review, but without liver histologic results (5
ases were excluded; n  58). The transplantation
ates of the study group (median transplantation year,
997; range, 1986-2003) were more recent than those
f the reference group (median transplantation year,
990; range, 1979-2003; P  .001). The onset of
-GVHD in the study group was acute in 22 cases, at
median of 34 days after allo-HSCT (range, 5-86
ays), and was chronic in 11 cases, at a median of 142
ays after allo-HSCT (range, 103-545 days). Seven
atients developed L-GVHD at a median of 25 days
range, 5-149 days) after DLI. Serum liver tests levels
able 1. Patient Characteristics
Variable
Histology Study G
(n  33)
ge, y, median (range) 27 (4–50)
ale sex 22 (66.7)
nderlying disease
AML 9 (27.3)
ALL 8 (24.2)
CML 7 (21.2)
MM 4 (12.1)
MDS 3 (9.1)
NHL 1 (3.0)
Others 1 (3.0)
isease status
CR1/CP1 9 (27.3)
More advanced 24 (72.7)
ource
BM 20 (60.6)
PBSC 13 (39.4)
After DLI 7 (21.2)
onor type
Related 28 (84.8)
HLA-identical 30 (90.9)
onditioning regimen
TBI based 31 (93.9)
Chemotherapy 2 (6.1)
VHD prophylaxis
CsA/MTX 21 (63.6)
T-cell depletion 12 (36.4)
nset of liver dysfunction
Acute 22 (66.7)
Chronic 11 (33.3)
nzymatic pattern
Cholestatic 15 (45.5)
Hepatitic 18 (54.5)
-GVHD consensus grading [9]
Stage 1 (bilirubin <3 mg/dL) 6 (18.2)
Stage 2 (bilirubin 3–6 mg/dL) 6 (18.2)
Stage 3 (bilirubin 6–15 mg/dL) 8 (24.2)
Stage 4 (bilirubin >15 mg/dL) 13 (39.4)
arget organs involved
Isolated liver 9 (27.3)
Skin and liver 9 (27.3)
GI tract and liver 1 (3.0)
Skin, GI tract, and liver 14 (42.4)
ML indicates acute myeloid leukemia; ALL, acute lymphoblastic le
myelodysplastic syndrome; NHL, non Hodgkin lymphoma; CR
PBSC, peripheral blood stem cells; DLI, donor lymphocyte infu
GI, gastrointestinal.
ata in parentheses are the percentage, except for in the age ranget the time of liver biopsy and the peak values are f
B&MTresented in Table 2. An unusual enzymatic hepatitic
attern, deﬁned by a marked increase of serum ami-
otransferase (alanine aminotransferase or aspartate
minotransferase) to more than 10 times the upper
ormal limit [13], was more common among patients
n the histology group than among those in the refer-
nce group (54.4% versus 18.9%; P  .001). Also,
atients who underwent liver biopsy were more likely
o experience isolated GVHD involvement of the liver
27.3% versus 3.4%; P  .001).
For the entire histology study group, the proba-
ility of NRM at 1 year from the onset of liver dys-
Reference L-GVHD Group
(n  58) P Value
26.5 (3–48) .950
37 (63.8) .783
.684
20 (34.5)
16 (27.6)
13 (22.4)
3 (5.2)
1 (1.7)
2 (3.4)
3 (5.2)
.098
26 (44.8)
32 (55.2)
55 (94.8) <.001
3 (5.2)
1 (1.7) .003
44 (75.9) .311
44 (75.9) .077
1.0
53 (91.4)
5 (8.6)
.001
16 (27.6)
42 (72.4)
.001
53 (91.4)
5 (8.6)
.001
47 (81.1)
11 (18.9)
.128
4 (6.9)
13 (22.4)
19 (32.8)
22 (37.9)
2 (3.4) <.001
23 (39.7)
2 (3.4)
31 (53.5)
; CML, chronic myeloid leukemia; MM, multiple myeloma; MDS,
complete remission; CP1, ﬁrst chronic phase; BM, bone marrow;
BI, total body irradiation; CsA, cyclosporin A; MTX, methotrexate;roup
ukemia
1, ﬁrst
sion; Tunction was 68.15%, with a median OS of 6.2 months
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8Figure 1A and B). The causes of NRM were infection
n  8), liver failure (n  4), hemorrhage (n  3), and
thers (n  3). Three patients died of relapse. We
ought to determine whether any of the histologic
eatures of the ﬁrst liver biopsy sample were of prog-
ostic value. LI was present in 25 cases. A higher
egree of LI, as deﬁned by Ishak et al. [15], was
ssociated with reduced NRM (P  .004) and im-
roved OS (P  .001). Patients with moderate or
evere LI (grades 2-3) were more likely to respond to
rimary treatment with steroids (P  .044), had a
ower NRM (P  .010; Figure 1C), and had a longer
edian OS (not reached versus 4.3 months; P  .012;
igure 1D) than those with mild or no LI (grades 0-1).
n addition to LI, the severity of HB [16] was associ-
ted with NRM (P  .001) and OS (P  .008) in our
eries. Patients with HB grade 0 or 1 had a lower
RM (P  .001; Figure 1E) and a longer median OS
7.1 versus 1.3 months; P  .004; Figure 1F) than
hose with grade 2 or 3. HB was not associated with
he response to primary treatment (P  .909).
istologic features consistent with a diagnosis of
-GVHD—including lymphocytic inﬁltration of the
ile ducts, portal inﬂammation, and ductopenia—were
ot associated with NRM (P  .541, P  .229, and
 .559, respectively) or OS (P .483, P .425, and
 .157, respectively). The most common ﬁnding
as bile duct damage. Neither the presence nor the
egree of bile duct damage was associated with clinical
utcome. No other histologic features examined (see
Patients and Methods”) had any statistically signiﬁ-
ant association with patient clinical outcome (data
ot shown).
We next investigated whether LI and HB in the
iver biopsy sample were associated with primary char-
cteristics of the patient or the transplant or with the
linical presentation of L-GVHD (Table 3). The clin-
cal onset (acute versus chronic) of L-GVHD was not
ssociated with the severity of LI or HB (P .105 and
 .967, respectively). The ﬁrst liver biopsy was
erformed a median of 14 days from the onset of
bnormal liver function tests, with a range from 4 to
8 days. The degree of LI and HB in the biopsy
able 2. Serum Liver Tests
Variable
Histology Stud
Time of Biopsy
otal bilirubin (<1 mg/dL) 8.48  8.25
LP (35-130 U/L) 540.4  352.4
ST (5-40 U/L) 209.4  178.5
LT (5-40 U/L) 415.8  356.1
GT (10-48 U/L) 816.8  565.3
GT indicates -glutamyl transpeptidase; ALP, alkaline phosphata
ormal range in brackets. P values refer to comparison of means o
ata are  SD.ample were not associated either with the time from (
08igure 1. The degrees of lobular inﬂammation and hepatocyte
allooning in the liver biopsy sample are associated with nonrelapse
ortality (NRM) and overall survival (OS) in patients with
-GVHD. A, The NRM in the study population was 68.15% (95%
I, 54.87%-81.43%) at 1 year. B, The median OS was 6.2 months,
ith a probability of OS at 1 year of 26.48% (95% CI, 15.34%-
7.62%). The effect is shown of the degree of lobular inﬂammation
n the ﬁrst liver biopsy sample (grades 0-1, solid line; grades 2-3,
ashed line) in NRM (C) and OS (D). The effect is also shown of
he degree of hepatocyte ballooning in the ﬁrst liver biopsy sample
grades 0-1, solid line; grades 2-3, dashed line) in NRM (E) and OSy Group Reference Group:
Peak Values P ValuePeak Values
18.25  17.64 16.56  15.46 .773
562.6  397.3 442.8  331.4 .164
217.8  209.7 286.4  298.2 .647
513.1  460.1 195.2  217.4 .098
902.8  737.5 728.6  762.5 .401
se; AST, aspartate aminotransferase; ALT, alanine aminotransferase.F). Crosses mark censored cases.
Table 3. Patient and Transplant Characteristics in Relation to the Degree of Lobular Inﬂammation and Hepatocyte Ballooning in the Liver Biopsy Sample
Patient
No. Sex Age (y) Disease
Donor
Type
Cell
Source
GVHD
Prophylaxis
Day of
Onset
Day of
Biopsy
Rx
at LB
TB
at LB (mg/dL)
Peak
TB (mg/dL)
ALT
at LB (IU/L)
AST
at LB (IU/L) LI HB Outcome
1 M 30 CML MR BM TCD 16 45 Yes 8.8 34.5 588 163 0 1 Dead
2 F 24 ALL MR BM CsA/MTX 35 34 Yes 2.3 4.3 579 104 0 1 Alive
3 F 47 AML MR PB CsA/MTX 190 21 Yes 3.0 9.5 617 607 3 1 Alive
4 M 17 AA MR BM CsA/MTX 63 29 Yes 1.9 1.9 221 105 1 0 Alive
5 M 32 AML MR PB CsA/MTX 110 40 Yes 1.1 6.1 565 589 2 0 Alive
6 M 31 MDS MR BM CsA/MTX 31 6 No 4.2 5.6 396 408 0 0 Dead
7 M 19 AML MR DLI TCD 19 12 Yes 14.9 24.4 374 173 1 1 Alive
8 F 4 ALL MR PB CsA/MTX 86 5 Yes 13.6 15.8 243 89 1 0 Dead
9 M 23 CML MR PB CsA/MTX 545 13 Yes 2.4 2.4 468 128 1 0 Dead
10 F 30 AML MR BM CsA/MTX 15 7 No 7.2 74.3 493 281 0 0 Dead
11 M 31 AML MU BM CsA/MTX 29 4 Yes 8.2 8.2 217 199 0 0 Alive
12 F 15 ALL MR PB CsA/MTX 75 7 No 3.9 39.4 622 404 1 0 Dead
13 M 27 MDS MR PB CsA/MTX 46 13 Yes 8.6 24.8 121 92 1 1 Dead
14 M 25 CML MR BM TCD 315 4 Yes 12.5 15.9 443 225 1 1 Dead
15 M 30 MM MR DLI TCD 11 31 Yes 1.6 2.9 834 294 1 1 Dead
16 M 44 MM MR BM CsA/MTX 143 68 Yes 0.8 1.0 66 51 2 0 Alive
17 M 22 ALL MR BM CsA/MTX 55 7 Yes 2.1 4.2 934 463 3 0 Alive
18 F 36 CML MR BM CsA/MTX 33 30 Yes 27.0 34.2 260 148 1 2 Dead
19 M 22 MDS MR PB CsA/MTX 103 26 Yes 1.4 1.7 590 174 2 1 Alive
20 M 29 ALL MU BM TCD 35 19 No 1.2 11.6 156 29 1 1 Dead
21 F 46 NHL MR PB CsA/MTX 43 19 Yes 9.5 22.2 133 68 0 1 Alive
22 F 33 MM MR DLI CsA/MTX 5 42 Yes 30.6 57.7 434 103 1 1 Dead
23 M 21 CML mMU PB CsA/MTX 40 21 Yes 26.6 37.2 660 263 1 2 Dead
24 M 13 CML mMU DLI TCD 25 5 Yes 22.5 25.5 58 46 1 0 Dead
25 M 24 AML MR BM CsA/MTX 142 14 No 3.6 4.6 312 167 1 0 Dead
26 M 30 CML MR DLI TCD 149 9 Yes 12.2 29.0 1885 747 1 0 Alive
27 F 28 AML MR PB CsA/MTX 41 21 Yes 2.5 36.0 128 172 2 1 Dead
28 M 7 ALL MR BM CsA/MTX 17 14 Yes 3.8 4.7 73 40 2 1 Alive
29 M 14 AML mMR PB TCD 120 40 Yes 3.4 5.0 301 130 0 3 Dead
30 F 47 AML MU BM TCD 136 9 Yes 6.7 7.3 47 25 2 1 Dead
31 M 12 ALL MR DLI TCD 29 14 Yes 11.5 12.5 667 168 0 1 Dead
32 F 50 MM MR DLI TCD 45 7 No 17.5 33.1 79 87 3 1 Dead
33 M 16 ALL MR BM TCD 109 25 Yes 3.2 4.9 278 168 0 0 Dead
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MM, multiple myeloma; MDS, myelod splastic syndrome; NHL, non-Hodgkin lymphoma;
AA, aplastic anemia; MR, matched related; MU, matched unrelated; mMR, mismatched related; mMU, mismatched unrelated; BM, bone marrow; PB, peripheral blood; DLI, donor lymphocyte
infusion; TCD, T-cell depletion; CsA/MTX, cyclosporin A/methotrexate; Day of Onset, from date of transplant; Day of Biopsy, from onset of liver dysfunction; Rx, on primary treatment with
steroids; TB, total bilirubin; LB, liver biopsy; LI, lobular inﬂammation; HB, hepatocyte ballooning; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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8he onset of liver dysfunction to the liver biopsy (P 
708 and P  .103, respectively) or with whether the
atter was performed before (6/33) or after (27/33) the
tart of primary treatment with steroids (P  .519 and
 .392, respectively). In addition, neither LI nor HB
as associated with the liver enzymatic pattern (hepa-
itic versus cholestatic; P .123 and P .667, respec-
ively) or with the clinical severity, as determined by
eak bilirubin level according to the Consensus Con-
erence on Acute GVHD Grading (P  .328 and P 
647, respectively) [9]. There was no statistically sig-
iﬁcant association between LI or HB and other pa-
ient or transplant-related characteristics, such as sex,
ge, underlying disease, donor type, cell source, DLI,
r GVHD prophylaxis (data not shown).
In line with previous studies and with our own
esults in the entire population including L-GVHD
atients without liver biopsy, the response to primary
reatment (yes versus no), bilirubin peak level (6
ersus 6 mg/dL), and GVHD prophylaxis (T-cell
epletion versus cyclosporin A/methotrexate) were
linical risk factors with a signiﬁcant effect on NRM
P  .001, P  .048, and P  .042, respectively) and
S (P  .001, P  .019, and P  .014, respectively)
4,7,9,11]. In a Cox regression analysis, LI and HB
ere independently predictive of NRM (RR, 5.14;
5% conﬁdence interval [CI], 1.14-23.18; P  .033;
nd RR, 0.18, 95% CI, 0.04-0.74; P  .018, respec-
ively) and OS (RR, 3.99; 95% CI, 1.13-14.14; P 
032; and RR, 0.23; 95% CI, 0.06-0.92; P  .037,
espectively). We therefore combined these features
o subdivide our cases into those with good (LI grades
-3 and HB grades 0-1; Figure 2, top), poor (LI grades
-1 and HB grades 2-3; Figure 2, bottom), and inter-
ediate (LI grades 0-1 or HB grades 2-3) histologic
isk. Patients in the poor histologic risk group had a
edian OS of only 1.3 months (95% CI, 1.1-1.5
onths), whereas patients with a good combined his-
ologic risk had signiﬁcantly better 1-year probability
f NRM (22.2%; P .001) and OS (65.8%; P .002).
ultivariate analysis including this combined histo-
ogic risk with the known signiﬁcant clinical prognos-
ic risk factors showed that both the response to pri-
ary treatment and the combined histologic risk had
n independent predictive effect on NRM (RR, 6.35;
5% CI, 1.45-27.87; P .014; and RR, 5.05; 95% CI,
.36-18.67; P  .015, respectively) and OS (RR, 4.70;
5% CI, 1.33-16.61; P .016; and RR, 3.31; 95% CI,
.07-10.27; P  .038, respectively). Neither bilirubin
evel nor GVHD prophylaxis entered the multivariate
odel.
ISCUSSION
No study to date has shown the histologic features
n the liver biopsy sample to have prognostic value in i
10atients with L-GVHD. For this study, we analyzed
n extended array of histologic features in addition to
hose traditionally associated with the diagnosis of
-GVHD. In addition, we limited the ﬁnal analysis to
atients with conﬁrmed diagnosis of L-GVHD and no
ther causes of liver dysfunction. No attempt was
ade to analyze the outcome, even with biopsy evi-
ence of L-GVHD, if a concomitant hepatic compli-
ation other than L-GVHD was present. This ap-
roach meant excluding a signiﬁcant proportion of
ases, thus reducing the sample size and potentially
imiting the statistical analysis, but it avoided any
igure 2. Histologic risk associated with the outcome of liver
VHD. Top: Liver biopsy sample from a patient with good histo-
ogic risk (see text) as deﬁned by marked grade 3 lobular inﬂamma-
ion, with many lymphocytes inﬁltrating liver cell plates, and min-
mal (grade 1) hepatocyte ballooning. Bottom: Liver biopsy sample
rom a patient with poor histologic risk, as deﬁned by widespread
rade 3 hepatocyte ballooning and the absence of lobular inﬂam-
ation (grade 0). The edge of a portal tract is present in the lower
art. Both pictures were taken with an Axiocam camera at 200
agniﬁcation in a Axioskop 2 microscope (Carl Zeiss Ltd., Herts,
K). Axiovision 3.0 software was used for acquisition, and Adobe
hotoshop 7.0 was used for image balance correction (stain, hema-
oxylin and eosin).nconsistency of judgment as to whether the outcome
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Histologic Features Predict the Outcome of Liver GVHD
Beﬂected the effect of L-GVHD or other processes. It
lso assumes, perhaps correctly, that most deaths after
n episode of L-GVHD are related directly or indi-
ectly to either L-GVHD or its treatment. Indeed, the
ajor cause of death in our patients was progressive
-GVHD complicated by infections, hepatic failure,
r bleeding.
Liver biopsies in patients with a clinical suspicion
f L-GVHD are normally performed to rule out other
reatable causes of liver dysfunction [11,12]. Thus,
-GVHD patients that undergo a liver biopsy are
elected for some patient characteristics. In our series,
nusual clinical presentation with a hepatitic enzy-
atic pattern or isolated liver involvement, chronic
nset, non–T cell–depleted grafts, and DLI-induced
-GVHD were more common in the histology study
roup than in the reference population. The retro-
pective nature of this study and the factors that in-
uence the clinical decision to request a liver biopsy
ay account for this patient selection. Other patient
haracteristics—such as sex, age, underlying disease,
isease status before transplantation, type of donor or
onditioning, and, more importantly, L-GVHD clin-
cal severity, as determined by serum bilirubin level
9]—were comparable between the histology study
roup and the reference L-GVHD cohort.
Our data in this cohort of patients with a con-
rmed diagnosis of L-GVHD suggest that simple
istologic features in the ﬁrst diagnostic liver biopsy
ay predict the outcome in terms of the probability of
response to treatment, NRM, and OS. In agreement
ith previous evidence [10-12], histologic features tra-
itionally linked to the diagnosis of L-GVHD had no
ssociation with NRM or OS and, therefore, were
nadequate for predicting patient outcome. However,
ur extended histologic analysis identiﬁed a strong
ssociation between the presence and degree of LI and
B in the ﬁrst diagnostic liver biopsy and patient
utcome. HB is a sign of liver cell damage that has
een associated with viral, autoimmune, and alcohol-
nduced hepatitis; ischemia; drugs; biliary obstruction;
nd cholestasis [17]. It has not yet been described as a
eature speciﬁcally associated with L-GVHD. Possible
echanisms of HB described in other settings include
rotein and oncotic water retention and dilatation
f the endoplasmic reticulum. Additional potential
echanisms in L-GVHD may include immune- and
ytokine-mediated effects, as well as drugs and pro-
onged cholestasis. However, we have not yet per-
ormed additional investigations to analyze this fur-
her, and the actual mechanisms in our series remain
ncertain. Presentation of L-GVHD as hepatitis, with
arkedly increased levels of aminotransferases, has
een reported, particularly after DLI [13,18-21]. In
ur patients, increased levels of aminotransferases
cutoff points were checked at 5-, 10-, and 15-fold the
pper normal limit for aspartate aminotransferase
B&MTnd alanine aminotransferase) and DLI-induced
-GVHD were not signiﬁcantly associated with each
ther (data not shown). In addition, they were not
ssociated with the presence or severity of LI or HB,
or, more importantly, were they associated with pa-
ient outcome. The degree of LI in our L-GVHD
eries was associated with the response to primary
reatment with steroids. Although speculative, the as-
ociation of higher LI with a better outcome may
ndicate that the disease is at an active immunologic
ffector phase, which may be more responsive to im-
unosuppression. It is interesting to note that in
hronic rejection of liver transplants, which bears sev-
ral similarities to L-GVHD, a histologically docu-
ented lobular hepatitic phase has been shown to
nticipate ductopenia and to be associated with an
mproved response to immunosuppressive treatment
22,23].
We examined the possibility that the effect of
istology on patient outcome was the result of indirect
ssociation of these histologic features with other pa-
ient or transplant factors. LI and HB were not asso-
iated with primary patient or transplant characteris-
ics (eg, sex, age, underlying disease, donor type, cell
ource, DLI, or GVHD prophylaxis) or with the time
rom transplantation to the clinical onset of liver ab-
ormalities (acute versus chronic). In this regard, oth-
rs have also shown that a hepatitic form of L-GVHD
ay occur early or late after allo-HSCT, indepen-
ently of the timing of the onset in the posttrans-
lantation period [21,22]. More importantly, in our
pinion, the presence and severity of LI and HB in
he ﬁrst diagnostic biopsy sample were independent
rom the timing of the biopsy from the clinical onset
f L-GVHD and were not associated with whether
he patients had started treatment with steroids at the
ime of the biopsy. These results suggest that the
rognostic effect of LI and HB in this patient popu-
ation is real and is not the result of the association of
hese features with individual factors or characteristics
hat may inﬂuence the outcome. Cox regression anal-
sis showed that the direct prognostic effects of LI and
B on NRM and OS were independent, and, when
ombined, the histologic risk posed by LI and HB
llowed the identiﬁcation of patients with an ex-
remely poor outcome and others with signiﬁcantly
etter NRM and OS. This prognostic effect of the
istologic risk on outcome maintained statistical sig-
iﬁcance in a multivariate analysis that included clin-
cal risk factors. Although the differences observed in
ur study are of a high order of magnitude and the
aplan-Meier curves are unequivocally distinct, our
elatively large collection of liver histologic data in
omparison with the literature available on this topic
till remains a small sample in statistical terms; there-
ore, our data need to be interpreted with caution.The assessment of the severity of GVHD relies on
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8linical changes incorporated into grading systems
8,9]. In addition, several studies have identiﬁed clin-
cal risk factors associated with the outcome of pa-
ients with GVHD of the liver and other target organs
2-5]. These are usually transplant- or patient-related
actors and cannot be modiﬁed or develop late (eg,
eak bilirubin level), so no timely action can be taken.
he need to investigate histologic and, perhaps, im-
unologic criteria to be included into grading systems
f GVHD to improve their current predictive value
as been recently highlighted [24]. Socié et al. [25]
ave recently reported seminal results showing that
athologic features from duodenal biopsy samples
ay have prognostic value in patients with gastroin-
estinal GVHD; this challenges the traditional view
hat the histologic severity of a given GVHD lesion is
nadequate to predict patient outcome [10]. In this
tudy, we analyzed a wide array of histologic features
n the ﬁrst diagnostic liver biopsy samples of a popu-
ation of patients with conﬁrmed diagnosis of
-GVHD and no other concomitant causes of liver
ysfunction. Our results show that LI and HB, histo-
ogic features not traditionally associated with the di-
gnosis of L-GVHD, may predict the probability of
esponse to treatment, NRM, and OS and that the
ombined histologic risk posed by LI and HB retains
ndependent prognostic value in a multivariate analy-
is including clinical prognostic factors. If conﬁrmed
y other studies, such information could inﬂuence the
ecision to undertake liver biopsy in patients with a
linical suspicion of L-GVHD and could expand cur-
ent indications, not only to exclude other causes of
iver injury, but also to predict clinical outcome, and
hould be considered in the selection of L-GVHD
atients for new experimental therapies and in the
esign of future trials. Prospective validation of our
ndings is warranted.
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